Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Nature Reviews Clinical Oncology, Published online: 29 February 2024; doi:10.1038/s41571-024-00868-0Patients with early stage hepatocellular carcinoma typically undergo resection, liver transplantation or local ablation; however, 30–50% will have disease recurrence at 3 years. The authors of this Review describe the tumour immune microenvironment and mechanism of action of immunotherapies, and discuss the available evidence from phase II/III trials of neoadjuvant and adjuvant treatment approaches in this setting.

Source: Nature Reviews Clinical Oncology - February 29, 2024 Category: Cancer & Oncology Authors: Josep M. Llovet Roser Pinyol Mark Yarchoan Amit G. Singal Thomas U. Marron Myron Schwartz Eli Pikarsky Masatoshi Kudo Richard S. Finn Source Type: research